دورية أكاديمية
Multiple receptor tyrosine kinases regulate dengue infection of hepatocytes.
العنوان: | Multiple receptor tyrosine kinases regulate dengue infection of hepatocytes. |
---|---|
المؤلفون: | Bourgeois NM; Department of Global Health, University of Washington, Seattle, WA, United States.; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States., Wei L; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States., Ho NNT; Department of Global Health, University of Washington, Seattle, WA, United States.; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States., Neal ML; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States., Seferos D; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States., Tongogara T; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States., Mast FD; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States., Aitchison JD; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States.; Department of Pediatrics, University of Washington, Seattle, WA, United States., Kaushansky A; Department of Global Health, University of Washington, Seattle, WA, United States.; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States.; Department of Pediatrics, University of Washington, Seattle, WA, United States. |
المصدر: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2024 Mar 22; Vol. 14, pp. 1264525. Date of Electronic Publication: 2024 Mar 22 (Print Publication: 2024). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media SA |
مواضيع طبية MeSH: | Dengue* , Dengue Virus*/physiology, Humans ; Receptor, EphA1 ; Hepatocytes/metabolism ; Tyrosine ; Virus Replication |
مستخلص: | Introduction: Dengue is an arboviral disease causing severe illness in over 500,000 people each year. Currently, there is no way to constrain dengue in the clinic. Host kinase regulators of dengue virus (DENV) infection have the potential to be disrupted by existing therapeutics to prevent infection and/or disease progression. Methods: To evaluate kinase regulation of DENV infection, we performed kinase regression (KiR), a machine learning approach that predicts kinase regulators of infection using existing drug-target information and a small drug screen. We infected hepatocytes with DENV in vitro in the presence of a panel of 38 kinase inhibitors then quantified the effect of each inhibitor on infection rate. We employed elastic net regularization on these data to obtain predictions of which of 291 kinases are regulating DENV infection. Results: Thirty-six kinases were predicted to have a functional role. Intriguingly, seven of the predicted kinases - EPH receptor A4 (EPHA4), EPH receptor B3 (EPHB3), EPH receptor B4 (EPHB4), erb-b2 receptor tyrosine kinase 2 (ERBB2), fibroblast growth factor receptor 2 (FGFR2), Insulin like growth factor 1 receptor (IGF1R), and ret proto-oncogene (RET) - belong to the receptor tyrosine kinase (RTK) family, which are already therapeutic targets in the clinic. We demonstrate that predicted RTKs are expressed at higher levels in DENV infected cells. Knockdown of EPHB4, ERBB2, FGFR2, or IGF1R reduces DENV infection in hepatocytes. Finally, we observe differential temporal induction of ERBB2 and IGF1R following DENV infection, highlighting their unique roles in regulating DENV. Discussion: Collectively, our findings underscore the significance of multiple RTKs in DENV infection and advocate further exploration of RTK-oriented interventions against dengue. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Bourgeois, Wei, Ho, Neal, Seferos, Tongogara, Mast, Aitchison and Kaushansky.) |
References: | PLoS One. 2016 Feb 22;11(2):e0149486. (PMID: 26901653) Int J Environ Res Public Health. 2019 Jun 28;16(13):. (PMID: 31261672) J Virol. 2017 Mar 29;91(8):. (PMID: 28148804) Nat Biotechnol. 2011 Oct 30;29(11):1039-45. (PMID: 22037377) J Virol. 2017 May 12;91(11):. (PMID: 28298606) Front Cell Infect Microbiol. 2022 Oct 14;12:926036. (PMID: 36310878) J Clin Invest. 2017 Apr 3;127(4):1338-1352. (PMID: 28240606) PLoS One. 2013;8(1):e55108. (PMID: 23372823) Antiviral Res. 2018 Jul;155:76-88. (PMID: 29758235) Arch Virol. 2021 May;166(5):1433-1438. (PMID: 33683474) Cell Rep. 2017 Dec 26;21(13):3900-3913. (PMID: 29281836) Antiviral Res. 2023 Jul;215:105622. (PMID: 37149044) Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):5048-53. (PMID: 24707051) Chem Pharm Bull (Tokyo). 2018;66(3):191-206. (PMID: 29491253) Virus Res. 2014 Aug 8;188:15-26. (PMID: 24704674) Front Microbiol. 2021 Dec 09;12:795756. (PMID: 34956164) Mem Inst Oswaldo Cruz. 2020 Feb 27;115:e190357. (PMID: 32130369) J Virol. 2022 Apr 13;96(7):e0196221. (PMID: 35266803) Virology. 2018 Mar;516:147-157. (PMID: 29358114) Cell Rep. 2018 May 8;23(6):1779-1793. (PMID: 29742433) Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20. (PMID: 25514926) J Gen Virol. 2018 Dec;99(12):1658-1670. (PMID: 30355397) PLoS One. 2013;8(1):e55018. (PMID: 23383040) Virology. 2014 Jan 5;448:15-25. (PMID: 24314632) Nature. 2016 Jul 7;535(7610):159-63. (PMID: 27383987) PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785. (PMID: 20706626) Virol J. 2016 Mar 01;13:35. (PMID: 26931565) Viruses. 2020 Jun 17;12(6):. (PMID: 32560467) Front Cell Infect Microbiol. 2021 Aug 26;11:715208. (PMID: 34513730) Life Sci Alliance. 2024 Mar 11;7(5):. (PMID: 38467420) Clin Infect Dis. 2016 Feb 15;62(4):468-476. (PMID: 26565005) Cell Rep. 2019 May 28;27(9):2579-2592.e6. (PMID: 31141684) Arch Virol. 2020 Mar;165(3):671-681. (PMID: 31942645) Curr Microbiol. 2021 Jan;78(1):17-32. (PMID: 33231723) Antiviral Res. 2021 Nov;195:105193. (PMID: 34687820) Viruses. 2023 Mar 30;15(4):. (PMID: 37112864) J Vis Exp. 2014 Feb 05;(84):e51149. (PMID: 24561642) J Travel Med. 2021 Dec 29;28(8):. (PMID: 34510205) Cell Chem Biol. 2021 Dec 16;28(12):1679-1692.e4. (PMID: 34216546) J Virol. 2020 Mar 17;94(7):. (PMID: 31915280) Nature. 2013 Apr 25;496(7446):504-7. (PMID: 23563266) Nat Commun. 2017 Nov 1;8(1):1232. (PMID: 29089541) Clin Microbiol Rev. 2020 May 13;33(3):. (PMID: 32404434) J Med Virol. 2020 Aug;92(8):941-955. (PMID: 31784997) J Immunol. 2013 Aug 15;191(4):1744-52. (PMID: 23851680) Front Immunol. 2018 Sep 26;9:2180. (PMID: 30319635) Antiviral Res. 2017 Jun;142:158-168. (PMID: 28238876) Virology. 2010 Jan 5;396(1):30-6. (PMID: 19897220) J Biomed Sci. 2009 Feb 04;16:17. (PMID: 19272179) In Silico Pharmacol. 2022 Sep 16;10(1):17. (PMID: 36119653) Virol Sin. 2021 Jun;36(3):412-423. (PMID: 33044659) Curr Opin Virol. 2020 Aug;43:9-21. (PMID: 32795907) J Ethnopharmacol. 2022 Jan 10;282:114627. (PMID: 34509603) Viruses. 2020 Jul 30;12(8):. (PMID: 32751420) Biomedicines. 2021 Jan 05;9(1):. (PMID: 33466394) Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658) Pathogens. 2022 May 24;11(6):. (PMID: 35745469) Cell Signal. 2018 Aug;48:64-68. (PMID: 29753850) Front Microbiol. 2021 Apr 30;12:682380. (PMID: 34017322) Rev Med Virol. 2022 Nov;32(6):e2360. (PMID: 35510480) Antiviral Res. 2018 Jul;155:67-75. (PMID: 29753658) Breast Cancer Res Treat. 2015 Aug;152(3):533-44. (PMID: 26195122) Cell Chem Biol. 2016 Apr 21;23(4):443-52. (PMID: 27105280) Pharmaceuticals (Basel). 2020 Jun 30;13(7):. (PMID: 32629797) J Biol Chem. 2015 Jul 10;290(28):17306-20. (PMID: 26032420) J Med Chem. 2015 Jun 25;58(12):4964-75. (PMID: 26039671) Mol Cell Proteomics. 2014 Nov;13(11):2836-54. (PMID: 24855065) EMBO Rep. 2022 Jun 7;23(6):e54041. (PMID: 35384245) Nucleic Acids Res. 2020 Jul 9;48(12):6824-6838. (PMID: 32432721) J Virol. 2013 Jul;87(13):7367-81. (PMID: 23616652) Front Cell Infect Microbiol. 2018 Nov 02;8:388. (PMID: 30450339) J Gen Virol. 2020 May;101(5):484-496. (PMID: 32141809) Nature. 2016 Jul 7;535(7610):164-8. (PMID: 27383988) Growth Factors. 2018 Aug;36(3-4):118-140. (PMID: 31084274) Lancet Infect Dis. 2014 Aug;14(8):706-715. (PMID: 24877997) Antiviral Res. 2017 May;141:7-18. (PMID: 28188818) Pharmacol Res. 2023 Jan;187:106552. (PMID: 36403719) Bing Du Xue Bao. 2012 Nov;28(6):652-7. (PMID: 23367565) Life Sci. 2017 Dec 15;191:180-185. (PMID: 29055802) Elife. 2020 Sep 08;9:. (PMID: 32897857) Cell Rep. 2016 Jun 28;16(1):232-246. (PMID: 27342126) Nat Med. 1997 Aug;3(8):866-71. (PMID: 9256277) Curr Opin Cell Biol. 2020 Apr;63:174-185. (PMID: 32114309) Expert Rev Anti Infect Ther. 2020 Mar;18(3):181-189. (PMID: 31971031) Int J Biol Sci. 2016 May 25;12(7):872-83. (PMID: 27313500) J Virol. 2020 Nov 23;94(24):. (PMID: 32999020) Thromb Haemost. 2010 Dec;104(6):1219-27. (PMID: 20886187) J Infect Dis. 2013 May 1;207(9):1442-50. (PMID: 22807519) Virol J. 2013 Apr 04;10:105. (PMID: 23557259) Virol J. 2022 Dec 31;19(1):228. (PMID: 36587218) Viral Immunol. 2020 Jan/Feb;33(1):61-70. (PMID: 31978319) PLoS Pathog. 2023 Mar 17;19(3):e1011241. (PMID: 36930690) Can J Microbiol. 2021 Oct;67(10):687-702. (PMID: 34171205) J Virol. 2021 Oct 13;95(21):e0131021. (PMID: 34379504) Int J Oncol. 2017 Jun;50(6):2221-2228. (PMID: 28498399) Curr Treat Options Infect Dis. 2023;15(2):27-52. (PMID: 37124673) Sci Rep. 2016 Jul 26;6:30490. (PMID: 27457684) PLoS One. 2022 Apr 15;17(4):e0267186. (PMID: 35427400) Virus Res. 2018 Sep 2;256:153-165. (PMID: 30130602) PLoS One. 2012;7(8):e41635. (PMID: 22927911) EClinicalMedicine. 2021 Jan 06;32:100712. (PMID: 33681736) Front Cell Infect Microbiol. 2022 Sep 12;12:979996. (PMID: 36171757) J Clin Microbiol. 2005 Jul;43(7):3267-72. (PMID: 16000446) Virology. 2013 Nov;446(1-2):303-13. (PMID: 24074594) Viruses. 2017 Aug 28;9(9):. (PMID: 28846635) PLoS Negl Trop Dis. 2012;6(9):e1820. (PMID: 23029581) Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3520-5. (PMID: 17360676) Nature. 2008 May 29;453(7195):672-6. (PMID: 18496526) Biochem Biophys Res Commun. 2017 Jan 29;483(1):58-63. (PMID: 28065855) |
فهرسة مساهمة: | Keywords: dengue (DENV); flavivirus; host-pathogen interactions; kinase regression; kinase signaling; neglected tropical disease |
المشرفين على المادة: | EC 2.7.10.1 (Receptor, EphA1) 42HK56048U (Tyrosine) |
تواريخ الأحداث: | Date Created: 20240408 Date Completed: 20240409 Latest Revision: 20240409 |
رمز التحديث: | 20240409 |
مُعرف محوري في PubMed: | PMC10995305 |
DOI: | 10.3389/fcimb.2024.1264525 |
PMID: | 38585651 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2235-2988 |
---|---|
DOI: | 10.3389/fcimb.2024.1264525 |